TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04352569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
Study: NCT02903836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Study: NCT00500500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGb 761® (Tanakan®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EGb 761® (Tanakan®)
Study: NCT00756743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04802540
Description: Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
Study: NCT03626766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photo in Verification Alert
Description: Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photo in Banner
Description: Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photo in Banner and Verification Alert
Description: Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
Study: NCT03808740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: atomoxetine 0.5 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: atomoxetine 0.5 mg/kg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill
Study: NCT04439188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K-beta Inhibitor GSK2636771
Description: Given PO
Study: NCT06353191

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT02119962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Study: NCT04413032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMS
Description: The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMS
Description: The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.
Study: NCT04414033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble: A New VR-AI Way of Treatment for Hot Flashes
Description: Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
Study: NCT02419833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate invasive intervention
Description: Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed invasive intervention
Description: Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery stenting
Description: Implantation of coronary stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery stenting
Description: Implantation of coronary stents
Study: NCT03543709

Intervention type: DIAGNOSTIC_TEST
Intervention: fibromyalgia 2013 criteria
Description: Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease

Intervention type: DIAGNOSTIC_TEST
Intervention: fibromyalgia 2013 criteria
Description: Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease

Intervention type: OTHER
Intervention: Behcet's disease current activity form
Description: Disease activity will be investigated in women with Behçet's disease without fibromyalgia.

Intervention type: OTHER
Intervention: Behcet's disease current activity form
Description: Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
Study: NCT02367625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoPop
Description: The new CryoPop device will be compared to standard cryotherapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedGyn MGC 200
Description: Standard cryotherapy
Study: NCT00754494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03356106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
Study: NCT01734135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Reminder
Description: A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
Study: NCT00756743

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules q12 hours for 10 days
Study: NCT02774538

Intervention type: OTHER
Group type: OTHER
Intervention: Agreement between oral and cervical HPV infection
Description: A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit.
Study: NCT00764413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 1 gram intravenous a day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 1 gram intravenous a day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chlorid
Description: Sodium chlorid 9mg/ml 500 ml per day in 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chlorid
Description: Sodium chlorid 9mg/ml 500 ml per day in 3 days
Study: NCT00817817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MF
Description: One evening dose of dry powder inhaled MF 400 μg (Multidose device).
Study: NCT02244515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
Study: NCT01526200

Intervention type: PROCEDURE
Intervention: Contrast-enhanced intraoperative ultrasound
Description: After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
Study: NCT00648414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1
Description: blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2
Description: tourniquet applied just below patch application site and above blood draw site, while samples collected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3
Description: tourniquet applied just above patch application site, while samples collected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Clinical Procedure 1
Description: blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Clinical Procedure 2
Description: tourniquet applied just below patch application site and above blood draw site, while samples collected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Clinical Procedure 3
Description: tourniquet applied just above patch application site, while samples collected
Study: NCT00176748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG 6013736
Description: 5 mg po bid
Study: NCT00509288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor
Description: Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10\^8 cells will be given up to 3x10\^11 anti-MART-1 F5 TCR engineered TIL or PBL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Study: NCT03516019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekend notices
Description: notifications sent on Saturday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekend notices
Description: notifications sent on Saturday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekend notices
Description: notifications sent on Saturday
Study: NCT00509288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -5 to 1: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -5 to 1: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e\^11 (with a minimum of 5x10e\^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e\^11 (with a minimum of 5x10e\^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
Study: NCT03795142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGB149
Description: Single Ascending Dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03268564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIVST-online promotion
Description: Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~1. Viewing a promotion video and a demonstration video~2. Brief motivational interviewing through telephone~3. Visiting the HIVST-online webpage~4. Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~1. Viewing a promotion video and a demonstration video~2. Visiting the HIVST-online webpage~3. Receiving a free self-testing kit and follow-up reminders
Study: NCT02009787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 tablets
Description: 2000 IU vitamin D3 tablets were taken daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: 2000 IU placebo tablets were taken daily for 6 months
Study: NCT01784302

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maalox Plus extra

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400 mg
Study: NCT04380142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Levodopa/Carbidopa (LD/CD)
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/Carbidopa (LD/CD)
Description: Oral encapsulated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI)
Study: NCT00538850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Description: In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to fentanyl sublingual spray.
Study: NCT01951391

Intervention type: OTHER
Group type: OTHER
Intervention: Control Hand Soap
Description: Commercially available soap will be used to wash the subject's forearms

Intervention type: OTHER
Group type: OTHER
Intervention: Control Hand Soap
Description: Commercially available soap will be used to wash the subject's forearms

Intervention type: OTHER
Group type: OTHER
Intervention: Benzalkonium Chloride Soap
Description: Commercially available soap containing benzalkonium chloride will be used to wash the subject's forearms

Intervention type: OTHER
Group type: OTHER
Intervention: Triclocarban Soap
Description: Commercially available soap containing triclocarban will be used to wash the subject's forearms
Study: NCT03208673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optive® Fusion + Optive® Gel Drop
Description: Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
Study: NCT02333448

Intervention type: BIOLOGICAL
Intervention: Blood sample taken on the day the treatment is initiated

Intervention type: BIOLOGICAL
Intervention: Blood sample taken on day 3 after initiation of treatment

Intervention type: BIOLOGICAL
Intervention: Blood sample taken on day 5 after initiation of

Intervention type: BIOLOGICAL
Intervention: Blood sample taken on day 7 after initiation of treatment

Intervention type: BIOLOGICAL
Intervention: Blood sample taken on day 10 after initiation of treatment
Study: NCT00265798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Study: NCT00574015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone/acetaminophen
Description: oral hydrocodone 10 mg/acetaminophen 650 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine (supraperiosteal nerve block)
Description: Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
Study: NCT01389687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactive Poliovirus Vaccine
Description: 0.5 mL, Subcutaneous
Study: NCT01533545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine with epinephrine
Description: Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain mepivacaine
Description: Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
Study: NCT02010502

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01959932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS 2.2)
Description: THS 2.2 ad libitum for 5 days in confinement

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Smoking abstinence (SA)
Description: SA for 5 days in confinement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette (CC)
Description: Subject's own preferred brand of CC ad libitum for 5 days in confinement
Study: NCT04025554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.
Study: NCT00749346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L
Description: TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
Study: NCT03837509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab SC
Description: Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
Study: NCT00963872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 50 mg/kg intravenously (IV) over 2 hours on Day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 50 mg/kg intravenously (IV) over 2 hours on Day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 40 mg/m\^2 over 1 hour on Days -6 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 40 mg/m\^2 over 1 hour on Days -6 through -2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy on Day -1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy on Day -1
Study: NCT00817817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MF
Description: One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).